Business Context and Reporting Period
Company: MRI Interventions, Inc. (Note: Metadata lists "Clearpoint Neuro, Inc.", but the filing identifies the registrant as MRI Interventions, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 6, 2013
Context: The Company entered into a material definitive agreement to amend a subordinated secured convertible note and a distribution agreement with Brainlab AG.
Key Financial Metrics
Debt and Liquidity:
- New Principal Balance: $4,289,444 (Amended and Restated Note).
- Composition of New Balance: $2,000,000 original principal + $389,444 accrued interest + $1,900,000 additional amount.
- Interest Rate: Reduced from 10% per year to 5.5% per year, effective March 6, 2013.
- Maturity Date: April 5, 2016.
- Repayment Terms: Principal and accrued interest payable in a single installment upon maturity.
The filing text does not provide a clear value for revenue, profit, cash flow, or operating margins.
Material Changes Versus Prior Period
Debt Restructuring:
- Conversion Feature Removed: The note is no longer convertible into shares of the Company's capital stock. Brainlab revoked a prior election to convert the note into common stock at $0.60 per share.
- Interest Rate Reduction: The annual interest rate was lowered from 10% to 5.5%.
- Principal Increase: The principal balance increased by $2,289,444 from the original $2,000,000 note, incorporating accrued interest and an additional $1,900,000.
- Covenants: The amendment permits prepayment and the incurrence of certain additional debt.
- The Co-Development and Distribution Agreement with Brainlab was amended to delete provisions pertaining to the equity conversion feature of the note.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the debt amendment and does not provide forward-looking guidance or general outlook statements.
Risks and Contingencies:
- Liquidity Obligation: The Company now has a fixed debt obligation of approximately $4.3 million due in a single lump sum in April 2016.
- Equity Dilution Avoided: The immediate risk of equity dilution from the conversion of the note was eliminated by the amendment.
Important Facts for Investor Verification
- Verify the source of the additional $1,900,000 added to the principal balance.
- Confirm the Company's current cash position and ability to service the $4,289,444 debt obligation at maturity in 2016.
- Review the full text of the Amended and Restated Note (Exhibit 4.1) for specific prepayment penalties or additional debt covenants.
- Clarify the relationship between the registrant name "MRI Interventions, Inc." and the metadata name "Clearpoint Neuro, Inc."